Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) shares gapped up before the market opened on Tuesday . The stock had previously closed at $10.75, but opened at $11.00. Theravance Biopharma shares last traded at $10.80, with a volume of 17,795 shares.
Analyst Upgrades and Downgrades
TBPH has been the subject of a number of recent analyst reports. Wall Street Zen raised Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Jones Trading upgraded shares of Theravance Biopharma to a "strong-buy" rating and set a $24.00 price objective for the company in a research report on Tuesday. Finally, HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday, February 25th. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $14.50.
Check Out Our Latest Research Report on TBPH
Theravance Biopharma Trading Up 0.1%
The stock has a market capitalization of $531.50 million, a PE ratio of -9.01 and a beta of -0.09. The business has a fifty day moving average price of $9.74 and a 200-day moving average price of $9.47.
Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.16). The firm had revenue of $15.39 million during the quarter, compared to analysts' expectations of $28.08 million. Theravance Biopharma had a negative net margin of 89.38% and a negative return on equity of 32.37%. On average, equities analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.
Insider Activity at Theravance Biopharma
In other Theravance Biopharma news, SVP Rhonda Farnum sold 24,000 shares of the firm's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $11.00, for a total value of $264,000.00. Following the completion of the sale, the senior vice president now directly owns 336,918 shares in the company, valued at $3,706,098. This trade represents a 6.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 6.90% of the stock is currently owned by company insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Aquatic Capital Management LLC bought a new stake in Theravance Biopharma during the fourth quarter worth about $25,000. GAMMA Investing LLC boosted its holdings in shares of Theravance Biopharma by 1,201.8% during the 1st quarter. GAMMA Investing LLC now owns 3,554 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 3,281 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Theravance Biopharma during the fourth quarter valued at approximately $69,000. AQR Capital Management LLC purchased a new position in shares of Theravance Biopharma in the 1st quarter worth $101,000. Finally, Teacher Retirement System of Texas purchased a new position in Theravance Biopharma in the fourth quarter worth about $103,000. Hedge funds and other institutional investors own 99.10% of the company's stock.
About Theravance Biopharma
(
Get Free Report)
Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.
See Also
Before you consider Theravance Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.
While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
